ProCE Banner Activity

Global Perspectives on the Implications of Key New Data With Targeted Therapy Combinations in Solid Tumors From ASCO 2021

Clinical Thought
Gain clinical perspectives from internationally recognized experts on key data from the 2021 ASCO virtual meeting. The CCO ASCO Virtual Conference Coverage program provides the information you need to understand and integrate the latest oncology data into your clinical practice.

Released: August 05, 2021

Expiration: August 04, 2022

Share

Faculty

Dirk Arnold

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

James Larkin

James Larkin, PhD, FRCP

Consultant Medical Oncologist
The Royal Marsden
London, United Kingdom

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Egbert F. Smit

Egbert F. Smit, MD, PhD

Professor of Pulmonary Medicine
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Eisai

Ipsen Biopharmaceuticals Inc

Faculty Disclosure

Primary Author

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Dirk Arnold, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, MSD, Pierre Fabre, and Roche; funds for research support from AstraZeneca, Bristol-Myers Squibb, and Pierre Fabre; fees for non-CME/CE services from Amgen, AstraZeneca, Bristol-Myers Squibb, MSD, Pierre Fabre, and Roche; and other financial or material support from AstraZeneca.

James Larkin, PhD, FRCP

Consultant Medical Oncologist
The Royal Marsden
London, United Kingdom

James Larkin, PhD, FRCP, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Ipsen, Novartis, Pierre Fabre, and Roche/Genentech.

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Isabelle Ray Coquard, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, Deciphera, GlaxoSmithKline, Mersana, MSD, and Roche.

Egbert F. Smit, MD, PhD

Professor of Pulmonary Medicine
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands

Egbert F. Smit, MD, PhD, has disclosed that he has received funds for research support from AstraZeneca, Daiichi Sankyo, Merck, MSD, and Novartis; consulting fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Lilly, Merck, MSD, and Novartis; fees for non-CME/CE services from Daiichi Sankyo, Lilly, and MSD; and other financial support from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, and Roche/Genentech.